ProofPilot, a New York-based clinical experience platform (CXP), has closed Series C funding.
Investors
The round was led by Sopris Capital with participation from Mitsui & Co. (U.S.A.), Inc.
Sopris Venture Capital is a multi-strategy investment firm with a single source of long-term strategic capital. The firm invests growth equity in technology-enabled business services and SaaS companies that solve critical pain points. Sopris partners with fast-growing companies that have a validated business model, proven product/market fit, and a strong management team.
ProofPilot Use of Funds
The company will use the funding to scale and enhance its platform.
About ProofPilot
Founded in 2014, ProofPilot provides clinical trial solutions for sites and participants. It supports clinical trials with its fully automated digital protocol platform for recruitment and conduct. Its platform, StudyCoPilot, is designed to centralize and simplify communication among sponsors, patients, and sites throughout the clinical trial process. It supports initiatives to improve diversity, equity, and inclusion (DE&I), streamline recruitment and retention, and reduce the burden on research sites. With its scalable capabilities, StudyCoPilot is now being deployed by industry-leading pharmaceutical clients on a global scale.
Funding Details
Company: ProofPilot, Inc.
Raised: Undisclosed
Round: Series C
Funding Month: July 2024
Lead Investors: Sopris Capital
Additional Investors: Mitsui & Co. (U.S.A.), Inc.
Company Website: https://www.proofpilot.com/
Software Category: Clinical Trial Solutions
Source: https://www.prnewswire.com/news-releases/proofpilot-announces-series-c-funding-302194206.html